Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
LITTLE ROCK, Ark. (AP) — A University of Arkansas for Medical Sciences startup company has received $14.5 million in federal grants to develop drug therapies aiming to help methamphetamine abusers break their addiction.
The company, InterveXion Therapeutics LLC, will develop therapies to reduce or prevent the euphoric rush that drug users crave by keeping methamphetamine in the bloodstream and out of the brain — where the drug exerts its most powerful effects.
The larger of the two grants — $9.55 million over three years— will support research to determine whether a methamphetamine vaccine may be safely advanced into a clinical trial with human participants.
The other grant of $5 million over three years will support production of the anti-methamphetamine monoclonal antibody that has been successfully tested in a first clinical study of healthy adults.
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
